About DAWNRAYS PHARMA Company

Dongrui Pharmaceutical was founded in December 1995 and is mainly engaged in the development, manufacture and sale of cephalosporic antibiotics and systemic specialty drugs. Dongrui Pharmaceuticals (Holdings) Limited was listed on the main board of the Hong Kong Stock Exchange on July 11, 2003, stock code: 2348. Dongrui Pharmaceutical (Holdings) Co., Ltd. is under nine subsidiaries, including Dongrui International Co., Ltd., Dongrui Biotech Investment and Development (Asia) Co., Ltd., Suzhou Dongrui Pharmaceutical Co., Ltd., Dongrui (Nantong) Pharmaceutical Technology Co., Ltd., Dongrui Anther (Hong Kong) Co., Ltd., Fujian Dongrui Pharmaceutical Co., Ltd., and Lanzhou Dongrui Pharmaceutical Co., Ltd. As a Hong Kong-listed company, the Group's overall decision-making management strictly complies with Hong Kong's corporate governance requirements, is globally oriented, has a global perspective and is inclusive of world culture, and is a company that investors can trust. Dongrui Pharmaceutical's cephalosporic antibiotic products include intermediates, raw anthers, and powder injections; specialty drugs cover the cardiovascular system, anti-hepatitis B virus, anti-allergy, digestive system, urinary system, and endocrine system, and dosage forms include tablets, capsules, and granules. In terms of the production of cephalosporin antibiotics, Dongrui Pharmaceutical has developed comprehensive production characteristics from pharmaceutical intermediates and raw materials to preparations. In particular, it has an advanced technology platform for third-generation cephalosporin synthesis, product quality has reached the international advanced level, and has built a cephalospore industry chain with a complete range of varieties, perfect comprehensive supporting functions, and high production capacity potential. It is the preferred raw material supplier for major domestic pharmaceutical manufacturers and many foreign pharmaceutical manufacturers. The Dongrui Pharmaceutical R&D Center was established in 2002 with nearly 50 core R&D personnel. It is a R&D team with professional and technical personnel as the backbone and composed of senior researchers such as doctorates and masters. The research and development direction mainly focuses on synthetic specialty drug imitation anthers. At the same time, it also takes into account the development of three new anthers and the exploration of some innovative anthers. The annual R&D investment accounts for about 10% of the sales amount of systemic specialty drugs. At present, Dongrui Pharmaceutical has established the “An” series of cardiovascular drug brands, and the Group's specialty drugs amlodipine benzenesulfonate tablets (amlodipine), losartan potassium hydrochlorothiazide tablets (Annexi), cetirizine hydrochloride tablets (cicovir), and entecavir dispersible tablets (Leyide) are the first batch of products approved for production and marketing in China, and the market share is among the highest. Dongrui Pharmaceutical has formed 4 sales teams according to different product lines, covering hospitals, distribution, raw materials, and import and export models. Currently, there are about 550 sales personnel, and it has more than 90 offices across the country, of which 40% are in first-tier cities and 30% in second-tier cities, so Dongrui Pharmaceutical has a good ability to quickly cover new products to hospitals. Dongrui Pharmaceutical has a perfect quality management system, and the existing plant is built in strict accordance with EU standards. Dongrui Pharmaceutical will always be committed to the cause of human health. With a high sense of social responsibility and forward-looking thinking, we will continue to provide safe and effective drugs to society through continuous technological innovation, and become a world-class pharmaceutical company, making the ultimate contribution to human health.